论文部分内容阅读
目的探究介入热化疗栓塞治疗巨块型原发性肝癌的治疗效果。方法选取高安市中医院2012年5月—2014年1月进行介入性热化疗的60例巨块型原发性肝癌患者作为观察组,选取同一时期进行经肝动脉化疗栓塞治疗的40例巨块型原发性肝癌患者为对照组。比较两组患者的临床疗效、生存质量,随访18个月,比较两组6个月、10个月、12个月、18个月的生存率、手术切除率。结果观察组总有效率、手术切除率高于对照组,差异有统计学意义(P<0.05)。两组Karnofsky评分比较,差异有统计学意义(P<0.05);观察组血清甲胎蛋白水平下降程度超过50%患者比例高于对照组,差异有统计学意义(P<0.05);术后10个月、12个月、18个月观察组患者的存活率高于对照组,差异有统计学意义(P<0.05)。两组患者毒副作用发生率比较,差异无统计学意义(P>0.05)。结论介入性热化疗治疗巨块型原发性肝癌的临床疗效显著,增加了二次手术的机会,是治疗巨块型原发性肝癌的一种安全、有效的方式。
Objective To investigate the therapeutic effect of interventional thermochemoembolization on massive hepatocellular carcinoma. Methods Sixty patients with giant hepatocellular carcinoma (HCC) who participated in the interventional thermochemotherapy from May 2012 to January 2014 in Gao’an Traditional Chinese Medicine Hospital were selected as the observation group. Forty cases of transcatheter arterial chemoembolization Type primary liver cancer patients as control group. The clinical efficacy and quality of life of the two groups were compared and followed up for 18 months. Survival and resection rates at 6, 10, 12 and 18 months were compared between the two groups. Results The total effective rate and surgical resection rate in the observation group were significantly higher than those in the control group (P <0.05). The difference of Karnofsky score between the two groups was statistically significant (P <0.05). The percentage of serum alpha-fetoprotein in the observation group was lower than 50% in the control group (P <0.05) The survival rate of observation group patients in months, 12 months and 18 months was higher than that in control group, with significant difference (P <0.05). There was no significant difference in the incidence of side effects between the two groups (P> 0.05). Conclusion Interventional thermochemotherapy is a safe and effective method for the treatment of massive hepatocellular carcinoma. The clinical effect of interventional thermochemotherapy is significant, which increases the chance of secondary surgery. It is a safe and effective way to treat massive hepatocellular carcinoma.